PAM Stock Recent News

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

PAM makes a strong case for investment, given its growth prospects, strong ROE, liquidity, better debt management and focus on clean power generation.

Pampa Energia S.A. (NYSE:PAM ) Q1 2025 Results Conference Call May 13, 2025 10:00 AM ET Company Participants Raquel Cardasz - Investor Relations Lida Wang - Investor Relations & Sustainability Officer Gustavo Mariani - Executive Vice President & Chief Executive Officer Horacio Turri - EVP & Executive Director of Exploration & Production Raquel Cardasz Good morning, everyone, and thank you for waiting.

Pampa Energía, a leading electricity producer in Argentina, holds a 15% market share and is highly diversified within the energy sector. The company operates in electric power generation, high-voltage power transmission, liquefied gas transportation, and has recently expanded into oil and gas extraction. Government measures under Alberto Fernández negatively impacted the energy sector, but conditions improved significantly during Milei's presidency.

BUENOS AIRES, ARGENTINA / ACCESS Newswire / May 12, 2025 / Pampa Energía S.A. (NYSE: PAM)(Buenos Aires Stock Exchange:PAMP), an independent company with active participation in Argentine oil, gas and electricity, announces the results for the quarter ended on March 31, 2025.

The price-to-sales ratio is a convenient tool to gauge the value of stocks incurring losses or in an early development cycle. Stocks like PCB, GIII, ROCK, PFE and PAM hold promise.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Launched Neurosterix with Perceptive Advisors, raising USD 65 million in Series A to advance preclinical portfolio Indivior selected GABAB PAM drug candidate and started IND enabling studies for development in substance use disorders Addex selected independent GABAB PAM drug candidate for development in chronic cough Repositioned our phase 2 mGlu5 NAM asset, dipraglurant in brain injury recovery Regained rights to our phase 2 mGlu2 PAM asset, ADX71149 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 25, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its full-year 2024 financial results for the period ended December 31, 2024 and provided a corporate update.

Utility stocks have long been a favorite for investors who are looking for stability and consistent returns in the current market.

Pampa (PAM) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.